📰 Floor Effect News
Floor Effect News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Floor Effect. Real-time updates on events, politics, business and more.
May 20, 2024
The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, seeking translational biomarkers and propelling more clinical...
February 23, 2024
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
December 26, 2023
NEW YORK, Dec. 26, 2023 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided an update on the grant...
December 7, 2023
Meeting Provided a Clear Path for Planned Phase 3b Trial NEW YORK, Dec. 7, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for...
November 20, 2023
Meeting will take place on December 6; Company plans to seek Special Protocol Assessment NEW YORK, Nov. 20, 2023 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. , a leading developer of adult...
October 18, 2023
- Path forward for ALS is a registrational Phase 3b U.S. clinical trial - - Biologics License Application to be withdrawn without prejudice - - Conference call and webcast at 8:30am ET today...
September 28, 2023
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
September 27, 2023
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
August 14, 2023
FDA advisory committee meeting to discuss NurOwn® for Amyotrophic Lateral Sclerosis scheduled for September 27, 2023 BrainStorms Biologics License Application for NurOwn has a Prescription... -Today at 07:06 am- MarketScreener
July 7, 2023
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, this week...